You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on cancer immunotherapy.
The firm's vaccine, which previously led to tumor regression in a patient with metastatic breast cancer, is scheduled to enter clinical trials in 2017.
Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.
The platform will be designed to gather all necessary data from a single RNA extraction, eliminating the need for flow cytometry, genomic sequencing, and expression profiling.
Tempus will sequence and analyze pancreatic and melanoma cancer data from Penn patients to identify patterns associated with a positive response to treatment.
Merck is hoping NanoString's multiplex platform can support gene expression signatures that will better predict which patients will respond to checkpoint inhibitors like its Keytruda.
Clinical MDx firm OmniSeq has been an early-access user of the research-use-only assay and is working on validating it to predict checkpoint inhibitor response.
The FDA-approved complementary assay "can provide insight into the survival benefit that may be achieved" with the treatment, Roche said.
The certification enables the company to offer its flow cytometry-based myeloid-derived suppressor cell assay for cancer patients.
Data for hundreds of breast tumors suggested specific signatures were more closely linked to tumor-infiltrating lymphocyte activity than was mutational load.
The deal will leverage BioNTech's IVAC Mutanome platform, which uses next-generation sequencing to identify targets for personalized mRNA-based vaccines.
The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine.
The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.
The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.
In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.